

Financial Tear Sheet

Corporate Profile

Iovance Biotherapeutics (formerly traded as Lion Biotechnologies) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). This approach, also known as adoptive T-cell therapy, was developed by Dr. Steven A. Rosenberg at the National Cancer Institute. In Phase 2 clinical trials conducted at the NCI, 56% and 24% of patients treated with this technology achieved objective and complete response criteria, respectively.

Our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma.

In addition to metastatic malignant melanoma, carcinoma of the head and neck and cervical cancer our TIL therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. As we continue advancing our current clinical programs through the introduction of manufacturing and logistical efficiencies aimed at decreasing production time and optimizing distribution processes, we aim to establish TIL therapy as a revolutionary, accessible, mainline cancer therapy.

Primary IR Contact

Solebury Trout

Annie Chang

Phone: 646-378-2972

E-mail:

achang@troutgroup.com

Stock Performance

IOVA (Common Stock)

Exchange NASDAQ (US Dollar)

Price **\$10.11**

Change (%) **▼ 0.13 (1.17%)**

Volume 258,486

52 Week High \$19.90

52 Week Low \$7.26

Market Cap \$1,260,024,271

Rolling EPS -1.36

PE Ratio 0

Shares Outstanding 123,169,528

Data as of February 20, 2019 12:38 p.m. ET



Recent Headlines

February 1, 2019

[Iovance Biotherapeutics to Present at Upcoming Investor and Medical Conferences](#)

December 21, 2018

[Iovance Biotherapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference](#)

November 13, 2018

[Iovance Biotherapeutics to Participate at November Investor Conferences](#)

Upcoming Events

There are currently no events scheduled.

SEC Filings

Filing Date	Form
February 14, 2019	SC 13G
February 14, 2019	SC 13G/A
February 14, 2019	SC 13G
February 13, 2019	SC 13G/A

Corporate Governance

Data provided by Nasdaq. Minimum 15 minutes delayed.